Our Firm is in the midst of investigating Xarelto lawsuits on behalf of individuals who were allegedly harmed by the blood thinner.
New York, NY (PRWEB) December 30, 2014
Less than a month after a federal panel voted to centralize similar Xarelto lawsuits (http://www.xareltolawsuit2015.com/) in a single proceeding, the newly-formed multidistrict litigation has scheduled its first status conference, Bernstein Liebhard LLP reports.
According to a Pretrial Order issued earlier this month, an initial status conference to discuss federal claims over the blood thinner will take place on January 29th, 2015 at 9:00 a.m. The meeting will convene in the U.S. District Court, Eastern District of Louisiana, where cases alleging life-threatening episodes of internal bleeding and other complications were transferred on December 12th. Plaintiffs in these Xarelto lawsuits allege that its manufacturer failed to adequately warn about these problems in its marketing of the drug. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our Firm is in the midst of investigating Xarelto lawsuits on behalf of individuals who were allegedly harmed by the blood thinner, we are pleased to see progress already occurring in the federal litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective devices and drugs including Xarelto. The Firm is currently offering free and confidential case evaluations to individuals who allegedly sustained life-threatening episodes of internal bleeding, strokes, deep vein thrombosis and/or pulmonary embolism caused by Xarelto.
All the Xarelto lawsuits that were transferred to the Eastern District of Louisiana last month accuse its manufacturers, Bayer Healthcare and the Johnson & Johnson subsidiary, Janssen Pharmaceuticals, of failing to properly warn about its product’s association with uncontrollable bleeding, pulmonary embolism, deep vein thrombosis, strokes and other serious problems. Plaintiffs further allege that Xarelto was wrongfully promoted as a more convenient alternative to warfarin, a decades-old medication used for similar purposes, but calls for dietary restrictions and the regular monitoring of blood levels. Although patients on warfarin may also experience episodes of internal bleeding, they can be reversed via the administration of Vitamin K. There is no available antidote to stop this side effect when it occurs in Xarelto users, which plaintiffs accuse the drug’s manufacturers of concealing from consumers.
Patients who allegedly sustained life-threatening episodes of Xarelto bleeding and other complications may be entitled to compensation for their injury related damages. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP